In the combination cohort, all patients with HCC or RCC had received at least one prior anti-PD-(L)1 therapy as part of standard of care and had discontinued the most recent anti-PD-(L)1 therapy for disease progression. The gene discussed is CD274; the disease is hepatocellular carcinoma.